Gland Pharma Ltd

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - The company reported a strong cash position with INR 24,795 million in cash and equivalents as of December 31, 2023. - Net cash position stood at INR 20,704 million after accounting for Cenexi's loans. - Cash flow from operations during the nine months was robust at INR 6,228 million. - Capex plans for expansion and operational improvements are being funded internally, including INR 810 million spent during the quarter. - No indication of external financing requirements or new debt/equity raises was discussed during the call.

- Cenexi capex plan: Around EUR30 million planned for this year and next to replace equipment and increase capacity (Page 11). - Gland Pharma capex: About INR300 crores expected in the next financial year for capacity expansions including Suite 9, Combi-line, and Pashamylaram Bag line (Page 12). - Cenexi high-speed ampoule line: Ongoing project to enhance capacity and operational efficiencies (Page 6). - Investments to build new high-speed lines, automate processes, and improve compliance at Cenexi to address operational issues and realize acquisition thesis over next 12-15 months (Page 4). - Ongoing tech transfer and approval processes for new programs at Cenexi expected to add EUR30-40 million incremental revenue medium-term (Page 4).

- Gland Pharma targets mid-teens percentage growth over the next 3-5 years on an ex-Cenexi basis, driven by complex product filings and new product launches. - The company expects continued revenue growth driven by U.S. market performance and incremental growth in Rest of the World (ROW) markets through tender wins (e.g., Saudi Arabia). - Growth is supported by increasing CDMO (contract development and manufacturing organization) revenues due to product transfers from clients. - The U.S. business has shown strong volume momentum with stable pricing and new product introductions, with the current quarterly run rate expected to sustain. - Cenexi's revenue growth is anticipated with additional projects and capacity enhancements, with break-even and profitability targets expected in 12-15 months. - India business is stable but less of a growth focus due to DPCO pricing regulations and smaller revenue contribution. - New product approvals in Australia, Europe, and South Africa will further contribute to growth.

- Gland Pharma targets mid-teens percentage growth on an ex-Cenexi basis over the next 2-3 years, driven by complex product launches and increased CDMO revenues. - Sustainable EBITDA margin of around 10% is expected for Cenexi starting FY 2025, with break-even anticipated within 12-15 months from Q3 FY24. - Cenexi's profitability hinges on operational improvements and capacity expansion, targeting EUR190-200 million revenues to generate positive EBITDA impact. - U.S. market growth remains strong with volume-driven revenue sustainability and stable pricing environment. - Indian market growth is limited due to DPCO price controls, contributing a smaller revenue share. - Incremental depreciation and amortization impact due to Cenexi’s PPA is estimated at INR 90 to 140 million per quarter, slightly affecting consolidated profits. - Operational efficiencies, new product filings, capacity upgrades, and contract manufacturing initiatives underpin future profit growth.

- The company has a strong order book and several transfer projects underway, indicating robust demand. - Operational challenges and regulatory approval processes are causing some near-term delays in order execution. - Capacity rebalancing and product line shifts are in progress to address these issues. - Planned investment in new high-speed automated lines aims to improve capacity and operational efficiency. - The acquisition of Cenexi and ongoing collaborations are expected to contribute incremental revenues in future. - Overall, the business sees mid-teens growth target over the next 2-3 years, reflecting confidence in order inflow and backlog.